The company’s Board of Directors approved the first interim dividend for FY26 of ₹28 per equity share (face value ₹2), amounting to ₹349.82 crore. The record date for the dividend has been fixed as November 10, with payment on or after November 20, 2025.
Ajanta Pharma said the growth was driven by a strong performance in its branded generics and US generics businesses. Revenue from branded generics in India rose 12% to ₹432 crore, while US generics revenue surged 48% to ₹344 crore.
For the first half of FY26, consolidated revenue grew 14% to ₹2,656 crore, and net profit rose 12% to ₹516 crore.The company said its Indian branded generics business outperformed the overall Indian Pharmaceutical Market (IPM), driven by higher volumes and new launches. Ajanta’s growth exceeded IPM growth by 32% during the period, led by ophthalmology and dermatology segments.
Ajanta Pharma operates seven manufacturing facilities across India and focuses on branded generics in India, Asia, and Africa, and generics in the US market.
At 1:40 pm, shares of Ajanta Pharma were trading 1.52% higher at ₹2,502.80 on the BSE, after opening at ₹2,483.60. The stock touched an intra-day high of ₹2,515.00 and a low of ₹2,462.20 so far.
Catch live market updates with CNBC-TV18.com’s blog
